FDA cracking down telehealth companies On March 2, the FDA announced it sent 30 letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites
Small volume: Ideal for subcutaneous injections of small volumes (0.3 to 1.0 ml)
Patients should maintain adequate fluid intake and seek urgent medical review if they are unable to keep fluids down
If you need to increase your dose, switch medications, or pause treatment, you communicate through the platform messaging system
In an attempt to manage GLP-1 costs, the plan considered tightening prior authorization criteria to limit GLP-1 approval for weight loss to only those with extreme obesity
Diabetologia, 56 (5), 965